Sugi Predict

Sugi Predict / Targets / SF1

SF1

Splicing factor 1 · Q15637 · SF1 on Sugi Atlas →

0 patent compounds predicted against SF1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SF1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Valproate and Levocarnitine in Children With Spinal Muscular Atrophy PHASE3UNKNOWN
WT1 for the Detection of Minimal Residual Disease PHASE2/PHASE3COMPLETED
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma PHASE2ACTIVE_NOT_RECRUITING
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer PHASE2COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Biocollection in MyeloDysplastic Syndrome (P-MDS) nanRECRUITING
Molecular Disease Profile of Hematological Malignancies nanUNKNOWN
SRSF2 Gene Mutation in Patients With t-MDS/AML nanCOMPLETED
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care nanCOMPLETED
Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples nanRECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS) nanRECRUITING
Genomic Services Research Program nanRECRUITING
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping nanUNKNOWN
Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF) nanCOMPLETED
GENOMED4ALL: Improving MDS Classification and Prognosis by AI nanUNKNOWN
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer nanUNKNOWN
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Clinical Study of Spinal Muscular Atrophy nanCOMPLETED
Mechanisms of Cell Death in Spinal Muscular Atrophy nanCOMPLETED
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes nanCOMPLETED
Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer nanCOMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
SMN Circular RNAs as Potential Biomarkers for the Therapeutic Response to Nusinersen in Spinal Muscular Atrophy Patients nanUNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia nanRECRUITING
RNA Sequencing in the Framingham Heart Study Third Generation Cohort Exam 2 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SF1 binder may also engage these)

ProteinNameSimilarity
Q64213 — 0.993 Q64213 →
WDR33 pre-mRNA 3' end processing protein WDR33 0.968 landscape →
Q8K4P0 — 0.964 Q8K4P0 →
Q640Q5 — 0.959 Q640Q5 →
Q8BIQ5 — 0.958 Q8BIQ5 →
KHSRP Far upstream element-binding protein 2 0.958 landscape →
Q8UVD9 — 0.957 Q8UVD9 →
Q3U0V1 — 0.957 Q3U0V1 →
Q58A45 — 0.957 Q58A45 →
A1L1C7 — 0.956 A1L1C7 →
Q8HXM1 — 0.956 Q8HXM1 →
Q9ULJ6 — 0.956 Q9ULJ6 →
O88874 — 0.956 O88874 →
Q8UUW7 — 0.956 Q8UUW7 →
P33240 — 0.955 P33240 →
Q8JGS0 — 0.955 Q8JGS0 →
Q9Z1X4 — 0.955 Q9Z1X4 →
SF3A1 Splicing factor 3A subunit 1 0.955 landscape →
Q5U231 — 0.953 Q5U231 →
ILF3 Interleukin enhancer-binding factor 3 0.953 landscape →
Q6GPM1 — 0.953 Q6GPM1 →
Q99PF5 — 0.953 Q99PF5 →
Q6P1E1 — 0.952 Q6P1E1 →
Q6PCR6 — 0.952 Q6PCR6 →
Q9JIL3 — 0.952 Q9JIL3 →
Q03369 — 0.951 Q03369 →
A2VDN6 — 0.951 A2VDN6 →
Q9H0L4 — 0.951 Q9H0L4 →
Q5RDA3 — 0.951 Q5RDA3 →
Q8R0S1 — 0.950 Q8R0S1 →